NKTR — NEKTAR THERAPEUTICS
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 906709 ·
Last close
$35.91
Market Cap
$1.23B
52W High
$109.00
52W Low
$33.40
ADV30
812,995
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 9,386,000 | — | -59,306,000 | -55,651,000 | 1,037,251,000 | 34,686,000 | 187,529,000 |
| Jun 2026 | 10,131,000 | — | -41,763,000 | -40,622,000 | 1,095,129,000 | 39,267,000 | 192,008,000 |
| Mar 2026 | 10,861,000 | — | -38,258,000 | -44,904,000 | 763,271,000 | 149,578,000 | 187,055,000 |
| Dec 2025 | 21,807,000 | 21,807,000 | -19,090,000 | -36,079,000 | 280,406,000 | 15,116,000 | 190,574,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-233,788,000
Investing CF
$-844,400,000
Financing CF
$1,074,466,000
CapEx
$-244,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-6.70
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,845,812,000
Inventory
—
Receivables
$4,756,000
ST Investments
$645,074,000
EBIT TTM
$-122,150,000
Pretax Income TTM
$-153,114,000
Interest Exp TTM
$30,964,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,185,000
EBITDA
$-157,759,008
Free Cash Flow
$-134,766,368
Enterprise Value
$788,133,248
Total Cash
$614,356,992
Total Debt
$128,668,000
Shares Out
34,142,994
Trailing EPS
$-18.92
Book Value
$24.86
ROE
-37.9%
ROA
-14.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 55,232,000 | -130,771,000 | -164,076,000 | 280,406,000 | 190,574,000 | 89,832,000 | -208,511,000 |
| Dec 2024 | 98,427,000 | -129,918,000 | -118,961,000 | 303,850,000 | 243,113,000 | 60,737,000 | -175,709,000 |
| Dec 2023 | 90,122,000 | -135,225,000 | -276,056,000 | 398,033,000 | 267,046,000 | 130,987,000 | -192,606,000 |
| Dec 2022 | 92,055,000 | -240,236,000 | -368,198,000 | 710,600,000 | 343,962,000 | 366,638,000 | -304,007,000 |
TTM Snapshot
Revenues TTM
$54,589,000
NetIncome TTM
$-157,127,000
OpCashFlow TTM
—
Assets (Latest)
$1,095,129,000
Forward EPS
$-10.31
Max Pain — expiry 2027-01-15
max pain strike: $45.00 · spot: $34.42 · call oi: 3,335 · put oi: 3,194Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.23B | $13.14 | — |
| SLN | Silence Therapeutics plc | $1.23B | $19.80 | — |
| SLNCF | Silence Therapeutics plc | $1.22B | $6.53 | — |
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
News headlines (Yahoo Finance, 1h cache)
Nektar (NKTR) Q3 2026 Earnings Call Transcript
2026-11-13 15:29 · Yahoo
Nektar Therapeutics Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call
2026-11-13 04:14 · Yahoo
Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 22:05 · Yahoo
Nektar: Q3 Earnings Snapshot
2026-11-12 21:28 · Yahoo
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
2026-11-12 21:15 · Yahoo
Nektar Therapeutics to Participate in Two Investor Conferences in November
2026-11-11 21:15 · Yahoo
How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors
2026-11-07 22:12 · Yahoo
Is Nektar Therapeutics (NKTR) Overvalued After A 407% Three Year Run?
2026-11-06 07:09 · Yahoo
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-29 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.